Reolysin Approval Status
- FDA approved: No
- Brand name: Reolysin
- Generic name: pelareorep
- Company: Oncolytics Biotech Inc.
- Treatment for: Ovarian Cancer, Pancreatic Cancer, Malignant Glioma
Reolysin (pelareorep) is a proprietary formulation of the human reovirus (Respiratory Enteric Orphan Virus) in development for the treatment of various cancers and cell proliferative disorders.
Development Status and FDA Approval Process for Reolysin
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.